Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer

• Status: Active, not recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary working hypothesis is that preoperative chemo-sensitivity testing using fluorodeoxyglucose positron emission tomography (FDG-PET) performed before and after one course of FOLFOX (folinic acid, fluorouracil, oxaliplatin) can identify the patients that will least likely have a significant benefit from adjuvant FOLFOX for stage III colon cancer. The benefit will be analyzed by correlating the preoperative FDG-PET uptake changes to the disease free and overall survival.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jules Bordet Institute

Criteria

Inclusion Criteria:

• Age 18 years or older

• Clinical/radiological evaluation compatible with stage III colon adenocarcinoma

• No prior chemotherapy

• No prior abdominal or pelvic irradiation

• WHO performance status 0 or 1

• Effective contraception during the study and the following six months

• Signed informed consent obtained prior to any study-specific screening procedures

• Tumour considered as curatively resectable (R0) based on standard preoperative evaluations

• White blood cell count ≥ 3×109/L with neutrophils ≥ 1.5×109/L, platelet count ≥ 100×109/L, haemoglobin ≥ 9 g/dL (5.6 mmol/L)

• Direct bilirubin ≤ 1.5×ULN; ASAT and ALAT ≤ 2.5×ULN; Alkaline phosphatase ≤ 2.5×ULN; Serum creatinine ≤ 1.5×ULN

• Delay between assessment of screening criteria and first PET/CT < 21 days

• Blood glucose < 150 mg/dl at the time of FDG administration. Insulin or oral anti-diabetic medication is not allowed on the days of PET/CT imaging.

• Compliance to the first chemotherapy course to be administered before surgery

• Delay between the first PET/CT imaging and the start of neoadjuvant FOLOFX < 7 days

• Second PET/CT imaging performed on D14 (range: D13-D15, with D1 as the first day of chemo administration)

• Delay between the second PET/CT and surgery < 7 days

• Stage III (ypTNM) as assessed after surgery

• CEA < 1.5 x ULN 1 month after surgery -

Exclusion Criteria:

• Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to screening. Incompletely healed wounds or anticipation of the need for major surgical procedure during the course of the study

• Any suspicion of metastatic disease

• Rectal cancer located within 15 cm from the anal verge by endoscopy or under the peritoneal reflection at surgery

• Inflammatory bowel disease

• Pregnancy (absence to be confirmed by ß-hCG blood test) or breast-feeding

• History or current central nervous system disease or peripheral neuropathy

• Hypersensitivity to any of the components of study treatments

• Previous malignancy in the last five years except basal-cell carcinoma of the skin or in situ cervical carcinoma

• Clinically relevant coronary artery disease or history of myocardial infarction in the last 6 weeks or high risk of uncontrolled arrhythmia

• Medical, geographical, sociological, psychological or legal conditions that would not permit the patient to complete the study or sign informed consent

• Any significant disease which, in the investigator's opinion, would exclude the patient from the study